C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $97.99M
• Dividend Yield: N/A
• Average Volume (3M): 1.25M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.39
• Revenue Growth: 98.56%
• EPS Growth: 37.97%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 71,007,080
• 10 Day Avg. Volume: 1,066,667
• 30 Day Avg. Volume: 1,252,444
• PEG Ratio: -0.09
• Price to Book (P/B): 0.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.60
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 0.97
• Enterprise Value/Gross Profit: 4.14
• Enterprise Value/Ebitda: -0.28
• 1Y Price Target: $11.88
• Price Target Upside: 760.87% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

C4 Therapeutics faces significant challenges with profitability and operational inefficiencies, leading to a low financial performance score. Technical analysis indicates bearish momentum, further weighing down the overall stock score. Valuation is constrained by negative earnings, making the stock less attractive. Without earnings call insights or notable corporate events, the score reflects the company's current financial and market challenges.

Positive Factors

Market Opportunity

CCCC's significant dislocation in the stock is viewed as a good opportunity to capture value generation.

Product Potential

CFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.

Negative Factors

Adverse Events

There were notable Grade 3 or higher treatment-related adverse events, such as neutropenia and anemia.

Regulatory Challenges

Ongoing discussions with regulators could delay the market approval of cemsidomide.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

C4 Therapeutics makes money primarily through collaboration agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific research, development, or regulatory milestones, and potential royalties on future product sales. The company may also generate revenue by advancing its proprietary drug candidates through clinical trials, ultimately aiming to bring them to market. Key revenue streams include milestone payments from existing collaborations and prospective revenue from future commercialization of its drug candidates.

C4 Therapeutics Financial Statement Overview

Summary

C4 Therapeutics shows potential with revenue growth but faces significant profitability challenges. The balance sheet is relatively stable with a solid equity position, yet negative returns highlight operational inefficiencies. Continued reliance on external financing for cash flow support suggests liquidity concerns. Overall, the company must improve its operational performance to enhance financial health.

Income Statement

C4 Therapeutics has experienced fluctuating revenue growth with a notable increase of 71.37% in TTM compared to the previous year. However, profitability remains a concern with negative net and EBIT margins. The gross profit margin improved significantly in the TTM period, but overall, the company struggles with operational inefficiencies reflected in persistent losses.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.30 in the TTM period, indicating manageable debt levels relative to equity. However, the equity ratio stands at 61.77%, reflecting a strong capital structure. The return on equity remains negative due to net losses, highlighting a need for improved profitability.

Cash Flow

C4 Therapeutics faces challenges with negative free cash flow growth and a high operating cash flow to net income ratio, mainly due to consistent operating losses. The reliance on financing activities to support cash flow is a concern, indicating potential liquidity risks.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
35.58M	20.76M	31.10M	45.78M	33.20M
	Gross Profit
35.58M	-96.95M	23.52M	42.88M	-44.27M
	EBIT
-119.61M	-139.03M	-129.53M	-82.13M	-60.45M
	EBITDA
-103.37M	-122.10M	-124.28M	-78.84M	-62.89M
	Net Income Common Stockholders
-105.32M	-132.49M	-126.50M	-86.04M	-66.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
244.90M	253.68M	337.12M	309.28M	371.69M
	Total Assets
349.60M	376.45M	430.84M	506.76M	400.14M
	Total Debt
65.76M	70.98M	87.15M	42.88M	22.92M
	Net Debt
10.26M	-55.61M	57.40M	-33.24M	-158.81M
	Total Liabilities
133.62M	130.34M	141.61M	117.16M	119.35M
	Stockholders Equity
215.99M	246.11M	289.23M	389.61M	280.79M
Cash Flow		Free Cash Flow
-65.34M	-108.55M	-111.44M	-88.24M	-67.90M
	Operating Cash Flow
-65.16M	-106.84M	-105.94M	-86.97M	-67.25M
	Investing Cash Flow
-51.27M	158.35M	58.42M	-189.34M	-190.50M
	Financing Cash Flow
45.34M	45.49M	1.15M	171.40M	348.93M

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Negative. The current price of 1.38 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.65, and below the 200-day MA of 4.04, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 42.04 is Neutral, neither overbought nor oversold. The STOCH value of 13.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
ZNTL	46 Neutral	$90.66M	―	-59.45%	―	―	48.92%
ZURA	43 Neutral	$68.68M	―	-62.34%	―	―	86.65%
CCCC	41 Neutral	$97.99M	―	-45.55%	―	98.56%	37.97%
CLYM	41 Neutral	$87.17M	―	-62.04%	―	―	-61.95%
KYTX	36 Underperform	$100.27M	―	-49.72%	―	―	―
VOR	33 Underperform	$22.11M	―	-125.43%	―	―	2.98%

C4 Therapeutics Corporate Events

C4 Therapeutics Updates on Cemsidomide Clinical Trial

On May 7, 2025, C4 Therapeutics announced updates from its Phase 1 clinical trial of cemsidomide, a small-molecule degrader for multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL). The trial’s dose escalation phase in MM is complete, with the 100 µg QD dose level showing a 50% overall response rate, including a complete response in one patient. The trial continues for NHL, with the maximum tolerated dose not yet reached. C4T plans to prioritize cemsidomide’s development and expects regulatory feedback by mid-2025 to support further clinical development in 2026. Financially, C4T reported a net loss of $26.3 million for Q1 2025, with cash reserves expected to fund operations into 2027.

Spark’s Take on CCCC Stock

According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.

C4 Therapeutics faces significant challenges with profitability and operational inefficiencies, leading to a low financial performance score. Technical analysis indicates bearish momentum, further weighing down the overall stock score. Valuation is constrained by negative earnings, making the stock less attractive. Without earnings call insights or notable corporate events, the score reflects the company’s current financial and market challenges.

To see Spark’s full report on CCCC stock, click here.

C4 Therapeutics Board Member Bruce Downey Retires

On April 10, 2025, Bruce Downey announced his retirement from the Board of Directors of C4 Therapeutics and will not stand for reelection at the 2025 Annual Meeting of Stockholders. His departure is not due to any disagreements with the company’s strategy or operations, and he will step down from various committee roles following the meeting.

Spark’s Take on CCCC Stock

According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.

C4 Therapeutics faces significant financial challenges, with issues in profitability and liquidity. The technical indicators suggest downward pressure on the stock price, and valuation metrics are not favorable. However, recent corporate events indicate strategic progress and potential for future growth. Overall, the stock score reflects these mixed signals, primarily weighted by financial and technical concerns.

To see Spark’s full report on CCCC stock, click here.